Aratana Therapeutics — Investor Presentation (October 2013)
20 slides from Aratana Therapeutics's investor presentation, Oct 16, 2013
Slide 1: A new beginning ... in pet biologics
Exhibit 99.2 A new beginning ... in pet biologics October 2013 ARATANA THERAPEUTICS Vet Exhibit 99.2
Slide 2: Special Note Regarding Forward-Looking Statements
Safe Special This fact approval initiatives; These factors including, substantial our regarding target in intellectual related common market “Risk SEC date 2forward-looking THERAPEUTICS ARATANA distribution inability should of Harbor presentation could animal Factors” forward-looking to that this in
Slide 3: Investment Highlights
Investment Large, De-risked Portfolio Private-pay Scalable Pure-play, 3The THERAPEUTICS ARATANA new growing and beginning approach drug first Highlights capital-efficient mover development market in pet therapeutics.
Slide 4: Vet Therapeutics: Strategic Rationale
Vet Strategic Biologics Oncology Early 4-Pipeline THERAPEUTICS ARATANA Vet Fast Good Dog Licensure If Full Mast Diagnostic licensure Therapeutics Therapeutics commercialization launch to lymphoma Cell fitbeyond market, Rationale (specifically, with isTumor, anticipated aopportunity achieved, may key
Slide 5: Deal Structure
Deal $43M $30.0M $3.0M 625,000 $5.0M 5-Significant THERAPEUTICS ARATANA Animal T-cell Combination Cash Due On Mastachievement Structure 12/31/2014 upfront pay Cell in rights at in health sellers’ earn-outs close interest restricted upside Tumor, retained ofpartnership debt cash, of to at Atopic regu
Slide 6: Pro-Forma Development Pipeline
Pro-Forma 2012 Development AT Dx T-Lymphoma B-Lymphoma* Mast Atopic Feline Additional Option Conditional Full Approval Decision *Partnered License 6ARATANA -Lymphoma License 001 002 003 2013 Cell Lymphoma Dermatitis Programs: 1 2 3 (Alpha) (Beta) (Gamma) (Pain) (Appetite (Post-Operative Tumor 2014 P
Slide 7: Translating the Promise of Biologics
Theyears TRANSLATING Biology Human 20 Pet Engineered 7ARATANA Biologics Promise Biologics underlying of knowledge, biologics THERAPEUTICS of Biologics THE Standard cancer for BEST and pets and of experience OF based Care immune HUMAN on existing conditions INNOVATION human are similar blockbuster TO
Slide 8: Oncology: Target-Rich Market
Oncology $57B $20B Rituxan Antibody Methotrexate Lomustine Mitoxantrone Cis-platinum Carboplatin L-asparaginase Prednisone Vincristine Doxorubicin Cyclophosphamide Chemotheraphy Avastin Erbitux Herceptin Campath Mylotarg Zevalin Bexxar Vectibix TheraCIM Leukemia, Sarcoma, Brain/CNS, Lymphomas Breast
Slide 9: A Highly Specific Pet Antibody Platform
AHigh VL CL CH2 heavy light VX Mouse Most Straightforward IP Pet Non Highly -Cost 9ARATANA Developed Compatible Engages proprietary protected Antibodies CH1 VH specific Fc Specific Proprietary immunogenic chain effective CH3 effective chain region yield specific potent pet THERAPEUTICS antibodies An
Slide 10: Intellectual Property
Intellectual US Claims Covers -Antibody Monoclonal Unpublished ARATANA 10 Additionally, Family Dependent Notice Covers Patent all directed of all ofConstant No. VX Allowance Property patents THERAPEUTICS VX Antibodies claims applications 8,337,842 products a to products divisional heterochimeric (ex
Slide 11: USDA/FDA Regulatory Path
FDA Chemistry, Labeling, Effectiveness USDA Proof File Manufacturing Field Preclinical Conditional Extended Full *Year 11 THERAPEUTICS ARATANA Conditional for Product 1Center and Safety ofYear -Product Center Concept USDA Field FOI Mfg. 2Product and for License Year licenses Summary, Safety for Vete
Slide 12: Canine Lymphoma: Ideal Target for Rituxan for Dogs
Canine Ideal RITUXAN A 6% Chemotherapy Clinical Lymphocyte Mast Lymphoma Sarcoma Hemangiosarcoma Mammary 12 THERAPEUTICS ARATANA Incidence Other Bone Skin canine-specific offor Cell total Lymphoma manifestations first dog FOR istargeting antibody most the iscancer DOG the most antibody common curren
Slide 13: B-cell Combination Therapy Remission Results
B-cell Combination 01Percent 50 100 150 Comparison Control Days 300 200 remission Treated 13 THERAPEUTICS ARATANA 00 Lymphoma Remission dogs is shown of received therapy Remission Treatment onincreases one Y-axis. Time cycle P<0.0007*** remission for of Chemotherapy the Control time Group alone Trea
Slide 14: T-Cell Lymphoma First Cohort Results
T-Cell First Cohort Primary Survival Study All Results Several Well 14 THERAPEUTICS ARATANA dogs in tolerated predicted Lymphoma of Class dogs endpoint at alive client-owned fixed alive Potential at<50% fixed time Treatment longer point time would dogs than point be would alivebe predicted
Slide 15: Antibody Positioning: Standard of Care in Canine Lymphoma
Antibody Standard Canine Lymphoma CD20 Value 15 THERAPEUTICS ARATANA will and Rituxan Campath of Positioning be CD52 phenotyping Care determined are in human moreallows byprecise lymphoma efficacy, B-cell immunotherapy toxicity comes and T-cell to andveterinary lymphomas ease targets of use medicine
Slide 16: Strategic Fit: PETX Pet Therapeutics Portfolio
Strategic Pet Cutting — PETX 16 THERAPEUTICS ARATANA AT-001 AT-002 AT-003 therapeutics portfolio edge Fit Appetite Pain Post-Operative science EP4 complementary as the Stimulant Receptor and exclusive innovation PainAntagonist Ghrelin Bupivicaine to focus cancer Agonist Liposome
Slide 17: U.S. Sales and Commercial Organization
U.S. 162014 +6 2015 + +1 17 THERAPEUTICS ARATANA Territory National Professional Customer Sales Inside 1Territory Regional Professional Pharmacovigilance Customer Sales Inside Sales Administration Sales Operations Sales Accounts Force Sales Managers Service Managers Sales Service Services Services D
Slide 18: Financing Sources and Uses
Financing No Uses Sources — Earn-outs 18 THERAPEUTICS ARATANA $30.0M $3.0M 625,000 $19.75M $10.0M $3M Balance Shares $5M financing of Funds ofupfront based to Overview Seller’s Funds in from Sheet shares from be contingency, cash on issued additional clinical, Cash paid PIPE paid Debton as for asdue
Slide 19: Expected Financial Profile and PIPE Investors
Our ~ Expect Non-dilutive AT-001/002/003/T-Cell -Current square Avalon MPMCAPITAL Institution Wellington Adage Marxe JPMorgan Jennison Principal D.E. Hutchin Kopp 19 THERAPEUTICS ARATANA 53,295 175,000 237,752 350,000 425,000 726,200 766,440 1,000,000 1,049,390 Shares OUS One Sufficient $10M Financi
Slide 20: Investment Highlights
Investment Large, De-risked Portfolio Private-pay Scalable Pure-play, The 20 THERAPEUTICS ARATANA newgrowing and beginning approach drug first Highlights capital-efficient mover development market in pet therapeutics.
Aratana Therapeutics — Investor Presentation (October 2013) on 6ix